Madison, Wisconsin, October 24, 2005
— The new ISO International Standard to detect and quantify N-nitrosodiethanolamine (NDELA) in personal care products is now available at Covance Inc. ( NYSE: CVD
), a leading provider of cGMP analytical services.
"Covance now supplies all the information and documentation about NDELA, enabling personal care product makers to confidently import into those markets where nitrosamine testing is required," says Tim Rhines, PhD, Associate Director of cGMP Pharmaceutical Analysis.
Covance offers the LC/MS/MS analytical chemistry method that specifically measures and detects NDELA to the European Union established tolerance of 50 micrograms/kilogram (ppb). Moreover, Covance supplies a faster, more efficient test. What took two days can now be executed in hours with greater accuracy.
Another benefit to personal care product makers is the introduction of total nitrosamine by GC/TEA, a new process that combines seven separate detection methods into one to capture all other nitrosamine. "Covance is one of only a few labs with this capability," add Rhines. "Total nitrosamine by GC/TEA will be more sensitive, and the bundling of the seven detection methods will make nitrosamine testing more cost effective."
Covance has a long history in testing and understanding nitrosamines. It developed the first AOAC method for testing unique N-nitrosamine compounds in the early 1970s, and has 15 years of experience supporting the personal care products industry through a wide range of cGMP analytical services.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in 18 countries, and more than 7,000 employees worldwide. Information on Covance's products and services, recent press releases , and SEC filings can be obtained through the Covance website.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.
Covance and the Covance logo are registered service marks of Covance in the United States and other countries.